10 biotech companies to watch in 2025
Dec 16, 2024 · Last year, we documented nine biotechs we thought you should watch in 2024. Now, as the year has flown by and the end of 2024 is approaching, biotech companies will be setting out their plans for next year as they continue to work towards bringing their innovative therapies through the clinic and to the market in an attempt to bring new and groundbreaking medicines to patients suffering from ...
Promising cure for COPD: is a breakthrough within reach?
Oct 9, 2024 · FDA approves two new COPD treatments in 2024 Verona Pharma’s Ohtuvayre. In June 2024, the FDA approved the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. The product, called Ohtuvayre (ensifentrine), was developed by Verona Pharma – a London-based company established 19 years ago to unlock the potential of ...
Ovarian cancer: BioNTech, Curelab, OvarianVax and more bring …
Dec 17, 2024 · In the long run, researchers aim to test the vaccine candidate more widely, across all those who are at a heightened risk of ovarian cancer. BioNTech’s mRNA vaccine causes antitumor effects but also side effects
Six biotech companies advancing multiple sclerosis therapies
Oct 24, 2024 · Biogen Leading multiple sclerosis drug candidate of Biogen: BIIB091 . Biogen is known for its pioneering work in the neuroscience field.It has been discovering and developing treatments for CNS disorders for more than 40 years, including treatments for multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, depression, lupus, and …
9 biotech companies advancing treatment for breast cancer in 2024
Nov 14, 2024 · Carrick Therapeutics. Lead candidate in breast cancer: Samuraciclib (CT7001) in phase 2; Technology: Oral cyclin-dependent kinase 7 (CDK7) inhibitor
Promising treatments for Charcot–Marie–Tooth disease
Nov 27, 2024 · NMD Pharma’s NMD670 launches phase 2 study for CMT patients. Last week, Denmark-based NMD Pharma began a phase 2a trial for NMD670, which scored Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) in June. “Patients with Charcot-Marie-Tooth are very excited about entering into this study.
Six bispecific antibody companies you should know about
Nov 19, 2024 · The bispecific antibody company is currently working with Summit Therapeutics on the development of ivonescimab. The candidate, originally discovered by Akeso, combines the power of immunotherapy through a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF – two targets critical for tumor growth and survival – into a single molecule.
Recent biotech deals: The 2024 tracker
January 2024: AbbVie and Umoja Biopharma, both based in the United States, are partnering to develop novel in-situ CAR-T cell therapies. Umoja is eligible to receive up to $1.44 billion for option exercise fees, development, and regulatory milestones.
Biotech in 2024: A retrospective
Dec 10, 2024 · This revival was further exemplified by Upstream Bio’s October debut, where shares opened 26.5% above the initial public offering (IPO) price, valuing the company at $1.1 billion.Overall, the healthcare sector, with biotech as a significant contributor, led U.S. IPO activities in 2024, accounting for 23% of total IPO proceeds and raising $6.6 billion.
Spinal cord injury: Are we getting closer to a treatment?
Oct 7, 2024 · Regenerating the spinal cord through cell therapy with Lineage’s OPC1. Cell therapy has emerged as a promising tool for treating spinal cord injuries aimed at promoting axonal regeneration and motor recovery. It involves the transplantation of cells that can directly support the repair of damaged tissues.